Immunocore Holdings Ltd (IMCR) - Net Assets
Based on the latest financial reports, Immunocore Holdings Ltd (IMCR) has net assets worth $396.56 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.10 Billion) and total liabilities ($705.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Immunocore Holdings Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $396.56 Million |
| % of Total Assets | 35.97% |
| Annual Growth Rate | 36.16% |
| 5-Year Change | 551.75% |
| 10-Year Change | N/A |
| Growth Volatility | 130.04 |
Immunocore Holdings Ltd - Net Assets Trend (2018–2024)
This chart illustrates how Immunocore Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Also explore IMCR total asset value for the complete picture of this company's asset base.
Annual Net Assets for Immunocore Holdings Ltd (2018–2024)
The table below shows the annual net assets of Immunocore Holdings Ltd from 2018 to 2024. For live valuation and market cap data, see Immunocore Holdings Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $360.72 Million | -2.20% |
| 2023-12-31 | $368.84 Million | +8.83% |
| 2022-12-31 | $338.90 Million | +46.38% |
| 2021-12-31 | $231.53 Million | +318.33% |
| 2020-12-31 | $55.35 Million | +182.84% |
| 2019-12-31 | $19.57 Million | -65.42% |
| 2018-12-31 | $56.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Immunocore Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 62058600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $135.00K | 0.04% |
| Other Comprehensive Income | $-33.76 Million | -9.36% |
| Other Components | $1.19 Billion | 329.93% |
| Total Equity | $360.72 Million | 100.00% |
Immunocore Holdings Ltd Competitors by Market Cap
The table below lists competitors of Immunocore Holdings Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Guizhou Redstar Developing Co Ltd
SHG:600367
|
$1.49 Billion |
|
Xiamen Meiya Pico Information
SHE:300188
|
$1.49 Billion |
|
JiLin Sino-Microelectronics Co Ltd
SHG:600360
|
$1.49 Billion |
|
Ruentex Industries Ltd
TW:2915
|
$1.49 Billion |
|
DoubleVerify Holdings Inc
NYSE:DV
|
$1.49 Billion |
|
V-Guard Industries Limited
NSE:VGUARD
|
$1.49 Billion |
|
Shanghai Zijiang Enterprise Group Co Ltd
SHG:600210
|
$1.48 Billion |
|
Ingersoll Rand (India) Limited
NSE:INGERRAND
|
$1.48 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Immunocore Holdings Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 368,843,000 to 360,716,000, a change of -8,127,000 (-2.2%).
- Net loss of 40,805,230 reduced equity.
- Other comprehensive income increased equity by 2,498,000.
- Other factors increased equity by 30,180,230.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-40.81 Million | -11.31% |
| Other Comprehensive Income | $2.50 Million | +0.69% |
| Other Changes | $30.18 Million | +8.37% |
| Total Change | $- | -2.20% |
Book Value vs Market Value Analysis
This analysis compares Immunocore Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.08x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 14.19x to 4.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $2.07 | $29.41 | x |
| 2019-12-31 | $0.72 | $29.41 | x |
| 2020-12-31 | $1.74 | $29.41 | x |
| 2021-12-31 | $5.28 | $29.41 | x |
| 2022-12-31 | $7.41 | $29.41 | x |
| 2023-12-31 | $7.54 | $29.41 | x |
| 2024-12-31 | $7.22 | $29.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Immunocore Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.47%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 2.80x
- Recent ROE (-11.31%) is above the historical average (-129.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -126.60% | -302.82% | 0.12x | 3.46x | $-77.29 Million |
| 2019 | -531.13% | -404.89% | 0.10x | 12.57x | $-105.89 Million |
| 2020 | -133.87% | -246.04% | 0.15x | 3.56x | $-79.63 Million |
| 2021 | -77.76% | -493.45% | 0.09x | 1.76x | $-203.18 Million |
| 2022 | -12.83% | -30.13% | 0.27x | 1.55x | $-77.35 Million |
| 2023 | -14.99% | -22.17% | 0.42x | 1.62x | $-92.17 Million |
| 2024 | -11.31% | -16.47% | 0.25x | 2.80x | $-76.88 Million |
Industry Comparison
This section compares Immunocore Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Immunocore Holdings Ltd (IMCR) | $396.56 Million | -126.60% | 1.78x | $1.49 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Immunocore Holdings Ltd
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat adv… Read more